Inebilizumab for Treatment of IgG4-Related Disease.
Stone JH, Khosroshahi A, Zhang W, Della Torre E, Okazaki K, Tanaka Y, Löhr JM, Schleinitz N, Dong L, Umehara H, Lanzillotta M, Wallace ZS, Ebbo M, Webster GJ, Martinez Valle F, Nayar MK, Perugino CA, Rebours V, Dong X, Wu Y, Li Q, Rampal N, Cimbora D, Culver EL; MITIGATE Trial Investigators.
Stone JH, et al. Among authors: dong l, dong x.
N Engl J Med. 2024 Nov 14. doi: 10.1056/NEJMoa2409712. Online ahead of print.
N Engl J Med. 2024.
PMID: 39541094